Nanomedicine 2019: Nanosilicas as bioactive substances, drug delivery means and activator of pharmacological action of natural or synthetic biologically active substances - L A Suvorova- Macrosor. LT, Europe | Abstract
international journal of bioassays.
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Nanomedicine 2019: Nanosilicas as bioactive substances, drug delivery means and activator of pharmacological action of natural or synthetic biologically active substances - L A Suvorova- Macrosor. LT, Europe

Author(s): L A Suvorova


Toxicoses caused by low-quality food, pharmaceutical treatment or environmental pollution can be successfully treated only due to the usage of different enterosorbents. (Nanosilicas) fumed silica is the most advantageous for binding toxins of protein origin. Moreover, they can deactivate pathogenic flora, act as a carrier of chemical and natural medicinal substances, and improve their biological activity. When used in combination with several types of biopolymers, they may regulate the release rate of active substances. The above-mentioned properties make competitive advantage over products with similar purposes, currently available on the market. Last time, it creates a wide range of composite systems based on nano-silica, which possess strong detoxifying effect, adaptogenic, antioxidant and immune-modulating properties, and to develop methods of action prolongation immobilized on the surface of silica carrier biologically active substances and development of efficient methods improving biological activity of antibiotics due to specific binding of them by silicas or their composites with biopolymeric agents. The most promising is the usage of medicinal products and biologically active additives, produced based on nano-silica, in industrial areas and for people with low-income. With the development of nanochemistry, the unique ability of nano oxides to participate in the structuration of the adjacent water layer was discovered. Because of the interactions between water and nanoparticles, interfacial water decomposes to produce a system nanosized water clusters separated by silica particles. It appears that properties of such nano-structured water are very different from the properties of bulk water. Such water is capable to have different dissolving abilities, for example, it does not dissolve polar compounds such as mineral acids and hydrogen peroxide, and also it may form weakly associated water domains with non-polar compounds and not participate in the formation of hydrogen bonds. As a result, upon contact of silica nanoparticles with cellular objects, a strong effect on cell metabolism occurs which is probably due to the retention of nutrients and stimulation of the receptor system near the cell membranes. Then, due to the interaction between the nanoparticles of silica-carrier and immobilized on its surface, biologically active substances stimulation of mucous membrane cells will occur, which leads to the growth of biological availability of the products. The main problem in the area of development and introduction of biologically active additives and pharmaceuticals is the conduction of pre-clinical and clinical trials. Conduction of such trials requires significant financial investments, which small and medium-sized enterprises usually can’t afford. At the present time Macrosorb LT company together with the Chuiko Institute of Surface Chemistry have developed a line of ready to use biologically active additives for detoxification of the body Silasita, characterized by high antioxidant and immune stimulating activity {Balzasil}, for lymph purification {Lymphoid}, series of fossils for preventive care and treatment of the number of diseases.


1. Swamy MK, Sinniah UR. Patchouli (Pogostemon cablin Benth.): botany, agrotechnology and biotechnological aspects. Ind Crops Prod. 2016;87:161–176. doi: 10.1016/j.indcrop.2016.04.032.        

2. Mohanty SK, Swamy MK, Sinniah UR, Anuradha M. Leptadenia reticulata (Retz.) Wight & Arn. (Jivanti): botanical, agronomical, phytochemical, pharmacological, and biotechnological aspects. Molecules. 1019;2017:22. 

3. Rodrigues T, Reker D, Schneider P, Schneider G. Counting on natural products for drug design. Nat Chem. 2016;8:531. doi: 10.1038/nchem.2479.            

4. Siddiqui AA, Iram F, Siddiqui S, Sahu K. Role of natural products in drug discovery process. Int J Drug Dev Res. 2014;6(2):172–204.    

5. Beutler JA. Natural products as a foundation for drug discovery. Curr Prot Pharmacol. 2009;46(1):9–11.        

6. Thilakarathna SH, Rupasinghe H. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients. 2013;5:3367–3387. doi: 10.3390/nu5093367.  

7. Bonifácio BV, da Silva PB, dos Santos Ramos MA, Negri KMS, Bauab TM, Chorilli M. Nanotechnology-based drug delivery systems and herbal medicines: a review. Int J Nanomed. 2014;9:1. doi: 10.2217/nnm.13.186.  

8. Watkins R, Wu L, Zhang C, Davis RM, Xu B. Natural product-based nanomedicine: recent advances and issues. Int J Nanomed. 2015;10:6055. 

9. Martinho N, Damgé C, Reis CP. Recent advances in drug delivery systems. J Biomater Nanobiotechnol. 2011;2:510. doi: 10.4236/jbnb.2011.225062.        

10. Jahangirian H, Lemraski EG, Webster TJ, Rafiee-Moghaddam R, Abdollahi Y. A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine. Int J Nanomed. 2017;12:2957. doi: 10.2147/IJN.S127683. 

11. Liu Z, Tabakman S, Welsher K, Dai H. Carbon nanotubes in biology and medicine: in vitro and in vivo detection, imaging and drug delivery. Nano Res. 2009;2:85–120. doi: 10.1007/s12274-009-9009-8.  

12. Orive G, Gascon AR, Hernández RM, Domínguez-Gil A, Pedraz JL. Techniques: new approaches to the delivery of biopharmaceuticals. Trends Pharmacol Sci. 2004;25:382–387. doi: 10.1016/            

13. Razzacki SZ, Thwar PK, Yang M, Ugaz VM, Burns MA. Integrated microsystems for controlled drug delivery. Adv Drug Deliv Rev. 2004;56:185–198. doi: 10.1016/j.addr.2003.08.012.            

14. Arayne MS, Sultana N, Qureshi F. nanoparticles in delivery of cardiovascular drugs. Pak J Pharm Sci. 2007;20:340–348.        

15. Patra JK, Baek K-H. Green nanobiotechnology: factors affecting synthesis and characterization techniques. J Nanomater. 2014;2014:219. doi: 10.1155/2014/417305.        

16. Joseph RR, Venkatraman SS. Drug delivery to the eye: what benefits do nanocarriers offer? Nanomedicine. 2017;12:683–702. doi: 10.2217/nnm-2016-0379.            

17. Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: a mini review. Int Nano Lett. 2014;4:94. doi: 10.1007/s40089-014-0094-7.        

18. Rudramurthy GR, Swamy MK, Sinniah UR, Ghasemzadeh A. Nanoparticles: alternatives against drug-resistant pathogenic microbes. Molecules. 2016;21:836. doi: 10.3390/molecules21070836.  

19. Lam P-L, Wong W-Y, Bian Z, Chui C-H, Gambari R. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern. Nanomedicine. 2017;12:357–385. doi: 10.2217/nnm-2016-0305.            

20. Haba Y, Kojima C, Harada A, Ura T, Horinaka H, Kono K. Preparation of poly (ethylene glycol)-modified poly (amidoamine) dendrimers encapsulating gold nanoparticles and their heat-generating ability. Langmuir. 2007;23:5243–5246. doi: 10.1021/la0700826.            

Share this article

International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.

International Journal of Bioassays [ISSN: International Journal of Bioassays] is licensed under
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© Copyright 2012-2024. All rights reserved.